BIOMAT Database Logo BIOMAT Database Logo

Interferon alfa-2b therapy for chronic hepatitis. 1997

J T Kirchner

UI MeSH Term Description Entries
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D006521 Hepatitis, Chronic INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors. Chronic Hepatitis,Cryptogenic Chronic Hepatitis,Hepatitis, Chronic, Cryptogenic,Hepatitis, Chronic Active,Hepatitis, Chronic Persistent,Chronic Active Hepatitis,Chronic Hepatitis, Cryptogenic,Chronic Persistent Hepatitides,Chronic Persistent Hepatitis,Hepatitis, Cryptogenic Chronic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D016898 Interferon-alpha One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways. Interferon Alfa,Interferon, Leukocyte,Interferon, Lymphoblast,alpha-Interferon,IFN-alpha D,IFN-alpha5,Interferon alpha-1,Interferon alpha-17,Interferon alpha-4,Interferon alpha-5,Interferon alpha-7,Interferon alpha-88,Interferon alpha-J,Interferon alpha-T,Interferon alpha4,Interferon alpha5,Interferon, Lymphoblastoid,Interferon, alpha,LeIF I,LeIF J,Leif D,IFN alpha D,IFN alpha5,Interferon alpha,Interferon alpha 1,Interferon alpha 17,Interferon alpha 4,Interferon alpha 5,Interferon alpha 7,Interferon alpha 88,Interferon alpha J,Interferon alpha T,Leukocyte Interferon,Lymphoblast Interferon,Lymphoblastoid Interferon,alpha Interferon

Related Publications

J T Kirchner
Interferon alfa-2b for chronic hepatitis B.
February 1991, The New England journal of medicine,
J T Kirchner
Therapy of chronic delta hepatitis with interferon alfa-2b.
January 1990, Journal of hepatology,
J T Kirchner
Interferon alfa-2b therapy in children with chronic hepatitis B.
January 1993, Gut,
J T Kirchner
r-Interferon alfa-2b/ribavirin combined therapy followed by low-dose r-interferon alfa-2b in chronic hepatitis C interferon nonresponders.
January 1999, Hepatology (Baltimore, Md.),
J T Kirchner
Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B.
August 2007, Antimicrobial agents and chemotherapy,
J T Kirchner
Treatment of chronic hepatitis B with interferon alfa-2b.
January 1990, Journal of hepatology,
J T Kirchner
Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C.
June 2001, Clinical pharmacology and therapeutics,
J T Kirchner
Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy.
June 2003, The Journal of clinical psychiatry,
J T Kirchner
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.
August 2001, Hepatology (Baltimore, Md.),
J T Kirchner
Treatment of chronic hepatitis C with recombinant interferon alfa-2b.
January 1993, Gut,
Copied contents to your clipboard!